Home › Funds › NVP Associates, LLC › MBX
NVP Associates, LLC position in MBX
MBX BIOSCIENCES INC · Health Care
NVP Associates, LLC reported holding 2,136,335 shares of MBX (MBX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$125.2M, representing 44.42% of its reported portfolio and ranking #1 among its reported holdings. NVP Associates, LLC has disclosed MBX holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How NVP Associates, LLC's MBX position evolved
NVP Associates, LLC first disclosed a stake in MBX in Q3 2024 at 2,136,335 shares (US$55.5M). The position peaked in Q3 2026 at 2,136,335 shares, worth US$125.2M. Across 9 filings, NVP Associates, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,136,335 shares valued at US$125.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 2.14M | $55.50M | New |
| Q4 2024 | 2.14M | $39.37M | Hold |
| Q1 2025 | 2.14M | $15.77M | Hold |
| Q2 2025 | 2.14M | $24.38M | Hold |
| Q3 2025 | 2.14M | $37.39M | Hold |
| Q4 2025 | 2.14M | $67.38M | Hold |
| Q1 2026 | 2.14M | $63.77M | Hold |
| Q2 2026 | 2.14M | $117.93M | Hold |
| Q3 2026 | 2.14M | $125.23M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MBX and 13F data
MBX (MBX BIOSCIENCES INC) is a Health Care company. 69 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$367.2M), NEA Management Company, LLC (US$199.5M), ORBIMED ADVISORS LLC (US$189.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MBX
- Frazier Life Sciences Management, L.P. 6.65M sh · $367.19M · Q2 2026
- NEA Management Company, LLC 3.61M sh · $199.52M · Q2 2026
- ORBIMED ADVISORS LLC 3.43M sh · $189.27M · Q2 2026
- Paradigm Biocapital Advisors LP 2.51M sh · $138.44M · Q2 2026
- Deep Track Capital, LP 1.73M sh · $95.64M · Q2 2026
- Aaron Wealth Advisors LLC 1.18M sh · $68.92M · Q3 2026
- Kynam Capital Management, LP 934.80K sh · $51.60M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 873.49K sh · $51.20M · Q3 2026
- Parkman Healthcare Partners LLC 800.17K sh · $44.17M · Q2 2026
- BRAIDWELL LP 710.88K sh · $39.24M · Q2 2026
- TCG Crossover Management, LLC 650.00K sh · $35.88M · Q2 2026
- Cormorant Asset Management, LP 550.00K sh · $30.36M · Q2 2026
More on NVP Associates, LLC
FAQ
How long has NVP Associates, LLC held MBX?
NVP Associates, LLC has disclosed MBX holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is NVP Associates, LLC's current position in MBX?
As of Q3 2026, NVP Associates, LLC holds 2.14M shares of MBX (MBX BIOSCIENCES INC), valued at $125.23M, representing 44.42% of its reported portfolio and ranking #1.
Has NVP Associates, LLC been buying or selling MBX?
In the latest 13F filing (Q3 2026), NVP Associates, LLC held unchanged its position in MBX. The position peaked in Q3 2026 at 2.14M shares.
Which other funds hold MBX?
Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., NEA Management Company, LLC, ORBIMED ADVISORS LLC, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.